MedTrace Logo

Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease

NCT03134820 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 352

Last updated 2017-05-01

No results posted yet for this study

Summary

Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related. Cancer patients with VT or PT are treated with low molecular weight heparins (LMWH) during at least 3 months, but nowadays the duration of treatment is not accurately determined.

The D-Dimer determination has been used like recurrence predictors after LMWH treatment suspension, but in cancer patients the useful is limited. Phospholipid-dependent microparticles could been used like recurrence predictors in cancer patients and tailored the duration of LMWH treatment for each patient.

Conditions

  • Venous Thromboembolism
  • Pulmonary Thromboembolisms
  • Cancer

Sponsors & Collaborators

  • Delos Clinical

    lead OTHER

Principal Investigators

  • Remedios Otero Candelera, MD PhD · Hospital Universitario Virgen del Rocío IBIS

  • Teresa Elias, MD PhD · Hospitales Universitarios Virgen del Rocío

  • Isabel Blasco, MD · Hospital Universitario Virgen Macarena

  • Maria Rodriguez, MD · Hospital Universitario de Valme

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-15
Primary Completion
2016-12-31
Completion
2017-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03134820 on ClinicalTrials.gov